Professor Paul G. Richardson summarizes the most important highlights in the field of Multiple Myeloma treatment after the 2024 ASH Annual Meeting.

Video: https://medicaldigest.org/scientific-contents/interview:management-multiple-myeloma-ash-2024

Kate Lathrop, MD discuss some of the high impact, clinically relevant, clinical trials that were presented at the San Antonio Breast Cancer Symposium 2024.

The studies discussed:

- (01:28) Circulating tumor DNA surveillance in ZEST, a randomized, phase 3, double-blind study of niraparib or placebo in patients w/ triple-negative breast cancer or HER2+ BRCA-mutated breast cancer with molecular residual disease after definitive therapy

- (07:15) Impact of Anthracyclines in High Genomic Risk Node-Negative HR+/HER2- Breast Cancer

- (13:02) No axillary surgery versus axillary sentinel lymph node biopsy in patients with early invasive breast cancer and breast-conserving surgery: Final primary results of the Intergroup-Sentinel-Mamma (INSEMA) trial

- (19:10) A Phase 2 Study of Neoadjuvant HER2-targeted Therapy +/- Immunotherapy with Pembrolizumab (neoHIP)

Video: https://medicaldigest.org/scientific-contents/interview:highligths-sabcs-2024

Janice Tsang, MD discusses early breast cancer updates at San Antonio Breast Cancer Symposium 2024.

Videó: https://medicaldigest.org/scientific-contents/interview:early-breast-cancer-updates

William G. Wierda, MD, PhD discusses current questions and state of the art treatement of chronic lymphocytic leukemia at the 2024 ASH Annual Meeting.

Video: https://medicaldigest.org/scientific-contents/interview:cll-highlights-ash-2024

Josef T. Prchal, MD investigated the genetic basis underlying elevated hemoglobin in Andean natives, Aymara, by using granulocyte transcriptome data from both Aymara and Europeans from La Paz, Bolivia. They found their differentially expressed and spliced genes are associated with inflammatory and HIFs pathways.

Video: https://medicaldigest.org/scientific-contents/interview:aymara-gene-tale-high-altitude-and-human-evolution

Aaron Gerds, MD, MS discusses the state of the art treatment in polycythemia vera at the 2024 ASH Annual Meeting.

Aaron Gerds, MD, MS discusses the state of the art treatment in myelofibrosis at the 2024 ASH Annual Meeting.

Video: https://medicaldigest.org/scientific-contents/interview:state-art-treatment-myelofibrosis

Cho Han Chiang, MD, MMSc presented an analysis at the 2024 ASH Annual Meeting, that shows GLP-1 receptor agonists led to a significant reduction in the risk for VTE among individuals with type 2 diabetes, compared with DPP-4 inhibitors, a recent indicated.

Video: https://medicaldigest.org/scientific-contents/interview:do-glp-1s-lower-vte-risk-people-type-2-diabetes

Rahul Banerjee, MD, FACP comments on the role of 24-hour urine testing in assessing multiple myeloma treatment responses at the 2024 ASH Annual Meeting.

Video: https://medicaldigest.org/scientific-contents/interview:24-hour-urine-testing-does-not-add-value-multiple-myeloma-response-assessments

Rahul Banerjee, MD, FACP discusses the state of the art treatment in Multiple Myeloma Care at the 2024 ASH Annual Meeting.

Video: https://medicaldigest.org/scientific-contents/interview:bridging-gaps-multiple-myeloma-care-community-oncologists-guide-navigating-evolving-treatment-landscape